Common Ph+ CML Adverse Events | CML Alliance
For Healthcare Professionals Outside the US
Send To a FriendPrint This PageChange Text Size

Common Adverse EventsCommon Adverse Events

The following is a summary of adverse events for TASIGNA®(nilotinib) and GLIVEC® (imatinib). For additional information, please click here to view the European SMPCs.

TASIGNA®
The most common nonhematologic adverse events that have been reported by patients taking TASIGNA® are1:

  • Rash
  • Pruritus
  • Nausea
  • Fatigue
  • Headache
  • Constipation
  • Diarrhea

Hematologic adverse events that have been reported by patients taking TASIGNA® are1:

  • Thrombocytopenia
  • Neutropenia
  • Anemia
  • Febrile neutropenia
  • Pancytopenia
  • Thrombocytosis
  • Leukocytosis

GLIVEC®
The most common nonhematologic adverse events that have been reported by patients taking GLIVEC® are2:

  • Fluid retention
  • Nausea and vomiting
  • Indigestion
  • Diarrhea
  • Itchy skin or rash
  • Painful joints
  • Muscle cramps
  • Headache

Hematologic adverse events that have been reported by patients taking GLIVEC® are2:

  • Neutropenia
  • Thrombocytopenia
  • Anemia
  • Pancytopenia


Next: Management Tips

Note: Before prescribing, please read full European Summary of Product Characteristics.

References

  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2007.
  2. GLIVEC® (imatinib) Summary of Product Characteristics. West Sussex, UK: Novartis Europharm Limited; 2010.